Biotech company Actinogen Medical has announced positive results for their lead drug Xanamem taking the ASX-listed company a step closer to creating a novel treatment for a disease that impacts more than 400,000 elderly Australians.
“These results are an important replication of previous trial findings also conducted in a cognitively normal population,” international cognition expert, Professor John Harrison, said.
“The positive effects on attention and working memory seen in the XanaMIA trial are a significant step in the development of a new treatment for Alzheimer’s Disease with a novel mechanism of action.”
In a release to the ASX, Actinogen reported that the trial had met its objectives with the efficacy endpoint of the Xanamem trial defined as clinically significant on the treatment on cognitive ability, and confirmed Xanamem’s ability to enhance attention and working memory whilst demonstrating a good safety profile.
“We are excited to see the positive clinical data for these lower Xanamem dose levels,” Actinogen’s CEO Dr Steven Gourlay said.
“Xanamem has the potential to be a novel daily oral therapy for Alzheimer’s Disease and other conditions that could be safely used alone or in combination with other therapies.
“Our future clinical trials will evaluate if Xanamem can make a significant improvement in the lives of patients and their families living with serious neurological conditions,” he said.
The Xanamem low dose-ranging trial was conducted in a population of 107 healthy, cognitively normal, older adults aged 50-80 years, with a mean age of 64 years and a gender ratio of one male to two females, with trial participants randomised to receive either 10 mg or 5 mg doses of Xanamem or matching placebo for a six-week treatment period.
It is the second trial conducted by Actinogen that has shown positive results for the potential treatment of Alzheimer’s by Actinogen’s lead drug Xanamem moving the company a big step closer to a groundbreaking treatment of a condition that impacts millions worldwide.
Professor Paul Rolan, Actinogen’s Chief Medical Officer, said the results consolidate demonstration of the positive effects of Xanamem on cognition, with excellent safety.
“They are a major boost to our Alzheimer’s Disease program and open the door to Xanamem’s evaluation in other chronic neurological and psychiatric diseases where poor cognition is a significant complaint,” he said.
Actinogen will now review detailed results of the Xanamem trial with academic and industry experts as it finalises the design of its next Alzheimer’s disease program trial.
Detailed results will be published at a future scientific congress and in a peer-reviewed journal.